Clinico-Genomic Database

Flatiron and Foundation Medicine’s real-world Clinico-Genomic Database (CGDB) integrates de-identified clinical data from electronic health records with comprehensive genomic profiling data.

Connect genomics with clinical outcomes

The CGDB allows researchers to accelerate precision oncology studies. Providing clinically meaningful data on 300+ genes sourced from 100k+ patient records, the CGDB enables both disease-specific and disease-agnostic analyses. Patient data from early through metastatic disease stages are included in the majority of datasets, with up to 3-month recency.

Features

Unlocking insights: Flatiron’s disease-specific and agnostic real-world data models

Disease-specific data models

The CGDB includes data on 20 disease types:

Acute myeloid leukemia
Advanced bladder cancer
Breast cancer
Chronic lymphocytic leukemia
Colorectal cancer
Diffuse large B-Cell lymphoma
Advanced endometrial cancer
Follicular lymphoma
Gastric/Esophageal/GEJ cancer
Head and neck cancer
Hepatocellular carcinoma
Mantle cell lymphoma
Melanoma
Multiple myeloma
Non-small cell lung cancer
Ovarian cancer
Pancreatic cancer
Metastatic prostate cancer
Renal cell carcinoma
Small cell lung cancer

Disease-agnostic data models

Our disease-agnostic datasets combine 20 disease-specific data models with a lighter-weight data model for all other histologies to enable robust pan-tumor analyses.

Comprehensive genomic profiling

The CGDB contains robust genomic profiling data across solid and liquid biopsies utilizing circulating tumor DNA (ctDNA), and offers complex biomarker information such as tumor mutational burden (TMB), microsatellite instability (MSI) status, and PD-L1 results.

By the numbers

100k+

Patients linked in the CGDB

300+

Genes in the CGDB

100+

Publications enabled with 15+ biopharma partners

Originally stemming from a high-priority need for real-world data, we were able to foster a new collaboration with Flatiron and Foundation Medicine and utilize their large data source of rich clinical and genomic data, representing a substantial proportion of community oncology patients nationally.

Hil Hsu, PhD, MPH Senior Manager, Center for Observational Research
Amgen

Source: ResearchX

Derive real-world endpoints using validated outcome variables

Real-world overall survival

Conduct robust survival analyses with our validated mortality variable, available with all CGDB subscriptions.

See validation study

Real-world progression-free survival

Analyze real-world progression-related endpoints across observational RWE studies with our validated real-world progression (rwP) variable, available with certain CGDB subscriptions.

See validation study

Real-world response endpoints

Analyze real-world response-related endpoints to support clinical development or regulatory decision making with our validated real-world response (rwR) variable, available with certain CGDB subscriptions.

See validation study